Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study

BACKGROUND: Oral semaglutide is the first glucagon-like peptide-1 receptor agonist (GLP-1RA) designed for oral administration; it offers a promising opportunity to facilitate an early approach to Type 2 Diabetes (T2D). The study aimed to evaluate, in a real-life setting, the effects of oral semaglut...

Descripción completa

Detalles Bibliográficos
Autores principales: Volpe, Sara, Lisco, Giuseppe, Fanelli, Margherita, Racaniello, Davide, Colaianni, Valentina, Lavarra, Valentina, Triggiani, Domenico, Crudele, Lucilla, Triggiani, Vincenzo, Sabbà, Carlo, De Pergola, Giovanni, Piazzolla, Giuseppina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534984/
https://www.ncbi.nlm.nih.gov/pubmed/37780624
http://dx.doi.org/10.3389/fendo.2023.1240263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534984/
https://www.ncbi.nlm.nih.gov/pubmed/37780624
http://dx.doi.org/10.3389/fendo.2023.1240263

Ejemplares similares